-
1 Comment
Procter & Gamble Health Limited is currently in a long term downtrend where the price is trading 9.3% below its 200 day moving average.
From a valuation standpoint, the stock is 140.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 11.5.
Procter & Gamble Health Limited's total revenue rose by 1.5% to $2B since the same quarter in the previous year.
Its net income has increased by 77.6% to $679M since the same quarter in the previous year.
Finally, its free cash flow fell by 51.5% to $734M since the same quarter in the previous year.
Based on the above factors, Procter & Gamble Health Limited gets an overall score of 2/5.
| ISIN | INE199A01012 |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Exchange | NSE |
| CurrencyCode | INR |
| Beta | 0.46 |
|---|---|
| Market Cap | 85B |
| PE Ratio | 35.86 |
| Target Price | None |
| Dividend Yield | 3.0% |
Procter & Gamble Health Limited engages in the manufacture and marketing of pharmaceuticals and chemical products in India and internationally. The company provides over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. The company was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India BV.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PGHL.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
